Document is current

Article History

Received: 24 November 2020

Revised: 26 May 2021

Accepted: 27 May 2021

First Online: 8 June 2021

Declarations

:

: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed (Regierung von Unterfranken, Bavaria, Germany (55.2–2531.01–73/13) and Landesamt für Natur, Umwelt und Verbraucherschutz, North Rhine-Westphalia, Germany (81–02.04.2018.A127)). This article does not contain any studies with human participants performed by any of the authors.

: Leoni Rolfes received travel reimbursements from Merck Serono and Sanofi Genzyme. Tobias Ruck received travel expenses and financial research support from Genzyme and Novartis and received honoraria for lecturing from Roche, Merck, Genzyme, Biogen, and Teva. Christina David: none. Stine Mencl: none. Stefanie Bock: none. Mariella Schmidt: none. Jan-Kolja Strecker: none. Steffen Pfeuffer received travel grants from Sanofi Genzyme and Merck Serono; lecturing honoraria from Sanofi Genzyme, Mylan Healthcare, and Biogen; and research support from Diamed, Merck Serono, and the German Multiple Sclerosis Society North Rhine-Westphalia. Andreas Schulte-Mecklenbeck received research support and travel expenses from Novartis. Catharina Gross received speaker honoraria from Mylan, Bayer Healthcare, and Sanofi-Genzyme and travel/accommodation/meeting expenses from Bayer Healthcare, Biogen, EUROIMMUN, Novartis, and Sanofi-Genzyme. She also received research support from Biogen and Novartis; her research is funded by the European Union (Horizon 2020), the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), and the Interdisciplinary Center for Clinical Studies (IZKF) Muenster. Michael Gliem: none. Jens Minnerup has received grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung (BMBF), Else Kröner-Fresenius-Stiftung, EVER Pharma Jena GmbH, and Ferrer International; travel grants from Boehringer Ingelheim; and speaking fees from Bayer Vital and Chugai Pharma. Michael Schumann: none. Christoph Kleinschnitz received honoraria for lecturing and consulting as well as financial research support from Ablynx, Almirall, Amgen, Bayer Vital, Bristol-Mayers Squibb, Biotronik, Boehringer Ingelheim, Biogen, CSL Behring, Daiichi-Sankyo, Desitin, Eisai, Ever Pharma, Sanofi Genzyme, Merck Serono, Mylan, MedDay, Novartis, Pfizer, Roche, Siemens, Stago, and Teva. Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.